Arcus Biosciences (RCUS) Asset Writedowns and Impairment (2024)
Arcus Biosciences (RCUS) recorded quarterly Asset Writedowns and Impairment of $20.0 million in Q1 2024.
Arcus Biosciences (RCUS) Asset Writedowns and Impairment (2024) Analysis & Trends
Arcus Biosciences' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $20.0 million for Q1 2024.
- In Q1 2024, Asset Writedowns and Impairment changed N/A year-over-year to $20.0 million; the TTM figure through Dec 2024 stood at $20.0 million (changed N/A YoY), while the FY2024 annual figure was $20.0 million, changed N/A from the prior year.
- Asset Writedowns and Impairment was $20.0 million for Q1 2024 at Arcus Biosciences.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $20.0 million in Q1 2024 to a low of $20.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Arcus Biosciences | 3.05 Bn | 2.23 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 20.00 Mn |
| Mar 31, 2024 | 20.00 Mn |